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OBJECTIVE — The mean amplitude of glycemic excursions (MAGE) is a signiﬁcant deter-
minant of overall metabolic control as well as increased risk for diabetes complications. Older
individualswithtype2diabetesaremorelikelytohavemoderatecognitivedeﬁcitsandstructural
changesinbraintissue.Consideringthatpoormetaboliccontrolisconsideredaderangingfactor
forcognitiveperformanceindiabeticpatients,weevaluatedwhetherthecontributionsofMAGE
to cognitive status in older patients with type 2 diabetes were independent from the main
markers of glycemic control, such as sustained chronic hyperglycemia (A1C), postprandial
glycemia (PPG), and fasting plasma glucose (FPG).
RESEARCH DESIGN AND METHODS — In 121 older patients with type 2 diabetes,
48-hcontinuoussubcutaneousglucosemonitoring(CSGM)wereassessed.MAGEandPPGwere
evaluated during CSGM. The relationship of MAGE to performance on cognitive tests was
assessed,withadjustmentforage,glycemiccontrolmarkers,andotherdeterminantsofcognitive
status. The cognitive tests were a composite score of executive and attention functioning and the
Mini Mental Status Examination (MMSE).
RESULTS — MAGE was signiﬁcantly correlated with MMSE (r  0.83; P  0.001) and with
cognition composite score (r  0.68; P  0.001). Moreover, MAGE was associated with the
MMSE (P  0.001) and cognition composite score (P  0.001) independently of age, sex, BMI,
waist-to-hip(WHR)ratio,drugintake,physicalactivity,meanarterialbloodpressure,FPG,PPG,
and A1C.
CONCLUSIONS — MAGE during a daily period was associated with an impairment of
cognitive functioning independent of A1C, FPG, and PPG. The present data suggest that inter-
ventional trials in older patients with type 2 diabetes should target not only A1C, PPG, and FPG
but also daily acute glucose swings.
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t is widely known that older individu-
als with type 2 diabetes are more likely
to experience cognitive decline than
thosewithouttype2diabetes(1).Theun-
derlying mechanisms, however, are still
unclear, but emerging evidence suggests
that a relationship between measures of
glucosecontrolandcognitivefunctionex-
ists (2). For instance, a cross-sectional
analysis in 378 high-functioning individ-
uals with diabetes showed that higher
A1Cbutnotfastingplasmaglucose(FPG)
levels were consistently associated with
lower scores on two cognitive tests (3).
Further evidence comes from studies us-
ing other indexes of dysglycemia, such as
postprandial glycemia (PPG) and acute
hyperglycemia (4,5). Therefore, despite
the fact that several studies have investi-
gated and compared the roles of the dif-
ferent glycemic indexes participating in
diabetic cognitive disorders, an accurate
assessment of their respective contribu-
tions is still difﬁcult. Considering that the
brainisdependentonanappropriatesup-
ply of glucose as its principal energy
source,onecannotruleoutthepossibility
that plasma glucose instability over 24 h
may affect cognitive functioning. From a
more practical point of view, exposure to
glycemic disorders can be described as a
function of two components: 1) the dura-
tion and magnitude of chronic sustained
hyperglycemia and 2) the acute ﬂuctua-
tions of glucose over a daily period (6,7).
The ﬁrst component was integrated by
A1C, which depends on both interpran-
dial and postprandial hyperglycemia, the
percentage of each contributor being
modulated by the degree of diabetic con-
trol (8). The acute ﬂuctuations of glucose
around a mean value is more difﬁcult to
assess, but the recent development of de-
vices that allow continuous glucose mon-
itoring on an ambulatory basis certainly
represents a new approach for studying
the inﬂuence of acute blood glucose ﬂuc-
tuations in real life (9). By applying this
technology, we have attempted to gain
further insight into the respective role of
both sustained chronic hyperglycemia
andacuteglucoseﬂuctuationsoveradaily
period on global cognitive functioning as
well as executive and attention function-
ing neuropsychological tests.
RESEARCH DESIGN AND
METHODS— A total of 121 older
outpatients with type 2 diabetes in Na-
ples, Italy, were included from 2007 to
2009. The patients were entered consec-
utively without any selection based on
A1C levels. Eligibility for the study was
based on a diagnosis over a minimum
1-year period. The main clinical and lab-
oratory characteristics of the patients are
given in Table 1. Frequency and duration
ofwalkingandotherleisure-timephysical
activities were assessed by interview. Ex-
clusion criteria, assessed with self-report
and medical records, included treatment
with steroids or nonsteroidal anti-
inﬂammatory drugs, acute concurrent
illnessduringthe3-monthperiodpreced-
ingtheinvestigation,andcerebrovascular
diseases. The study was conducted after
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consent.
Subcutaneous interstitial glucose lev-
els were monitored on an ambulatory ba-
sis over a period of 3 consecutive days by
using continuous subcutaneous glucose
monitoring (CSGM) (GlucoDay; A.
Menarini Diagnostics, Florence, Italy) as
describedpreviously(10).Thesensorwas
insertedonday0andremovedonday3at
mid-morning.Thedataweredownloaded
to a computer for evaluation of glucose
variations, but calculations of glucose
variations were limited to data obtained
on days 1 and 2 to avoid bias due to both
insertion and removal of the sensor and,
thus, to insufﬁcient stabilization of the
monitoring system. The characteristic
glucose pattern of each patient was calcu-
lated by averaging the proﬁles obtained
on study days 1 and 2. Standardized meal
tests with 24-h sampling comprising
three mixed meals were performed on
days 1, 2, and 3. After an overnight fast,
patients received medications at 0700 h
and consumed breakfast 30 min after
treatment. Lunch and dinner were pro-
vided 5 and 10 h after the beginning of
breakfast, respectively. The standardized
breakfastcontained419kcal(57%carbo-
hydrate, 17% protein, and 26% fat),
lunch contained 692 kcal (66% carbohy-
drate, 16% protein, and 18% fat), and
dinnercontained507kcal(41%carbohy-
drate, 26% protein, and 32% fat). Before
enrollment, all patients underwent ca-
rotid ultrasound examination and mag-
netic resonance imaging (MRI) for the
screening of carotid atherosclerosis and
white matter lesions, signiﬁcant signs of
cortical or subcortical atrophy. Patients
with alterations in MRI scans such as
whitematterlesionsorcorticalorsubcor-
tical atrophy were considered lost to fol-
low-up analysis because morphological
brain lesions as evidenced by MRI might
affect cognitive functioning indepen-
dently of the changes in metabolic con-
trol. All MRI evaluations were made by
physicians not involved in the study and
blinded to the study design. In brief, all
patients were investigated in the supine
position with the head slightly turned
from the sonographer. The carotid arter-
ies were carefully examined for wall
changes from different longitudinal and
transverseviews.Thecommoncarotidar-
tery, the carotid bulb, and the internal
and external carotid arteries were exam-
ined in all subjects. A region 1.5 cm
proximal to the carotid bifurcation was
identiﬁed, and the intimal-media thick-
ness of the far wall was evaluated as the
distance between the luminal-intimal inter-
face and the medial-adventitial interface.
One transversal and two longitudinal
measurementsofintimal-mediathickness
wereobtainedfrom10contiguoussitesat
1-mm intervals, and the average of the 10
measurements were used for the analysis.
All ultrasound measurements were per-
formed before enrollment by two trained
investigators who were unaware of the
study protocol.
Laboratory measurements
Blood samples for the assay of insulin
werecollectedinEDTAtubes,andplasma
was immediately aliquoted in Eppendorf
vials and stored at 80°C until thawed
forassays.Plasmainsulinwasdetermined
by a commercial double-antibody, solid-
phase radioimmunoassay (Sorin Bio-
medica,Milan,Italy)(intra-assaycoefﬁcient
of variation 3.1  0.3%; cross-reactivity
vs. proinsulin 0.9%). Serum glucose, se-
rum lipid, and serum lipoprotein were
quantiﬁedfromfreshsamplesdrawnafter
participants had been fasting for at least
12 h. The serum glucose level was deter-
minedbyanenzymaticcolorimetricassay
using a modiﬁed glucose oxidase-
peroxidase method (Roche Diagnostics,
Mannheim, Germany) and a Roche-
Hitachi 917 analyzer. Commercial enzy-
matic tests were used for determining
serum total and HDL cholesterol and tri-
glyceride (Roche Diagnostics) levels.
Assessment of glycemic instability
The mean amplitude of glycemic excur-
sions (MAGE), which has been described
by Service et al. (11), was used in the
present study for assessing glucose ﬂuc-
tuations during 24 h. In particular, we
used the glucose proﬁles obtained from
continuous glucose monitoring system
dataonstudydays1and2,i.e.,fromcon-
tinuous monitoring for 48 h. This param-
eter was designed to quantify major
swings of glycemia and to exclude minor
ones. For this reason, only increases of
1 SD of the mean glycemic values were
taken into account. Calculation of the
MAGE was obtained by measuring the
arithmetic mean of the differences be-
tweenconsecutivepeaksandnadirs;mea-
surement in the peak-to-nadir or nadir-
to-peak direction was determined by the
ﬁrst qualifying excursion. The measure-
ment of this parameter, which has been
proved to be independent of mean glyce-
mia, is of particular interest because the
greater the MAGE, the higher the glyce-
mic instability (12).
Assessment of cognitive functions
Twenty-four to 48 h before CSGM, global
cognitive function was assessed with the
Mini-Mental State Examination (MMSE)
corrected for educational levels of pa-
tients (13). This cognitive test covers
many cognitive skills, and scores range
from 0 to 30. The Trail Making Test
(TMT) is a visuomotor speeded task that
consists of two parts: TMT-A and TMT-B.
TMT-A, a visual scanning test, requires
onetodrawalineconnectingconsecutive
numbers from 1 to 25. TMT-B adds cog-
nitive ﬂexibility to TMT-A and requires
one to draw a line connecting numbers
and letters in alternating sequence (14).
Although time-to-completion scores are
typicallyusedtoexamineaspectsofatten-
tion and executive function, the differ-
Table 1—Clinical characteristics of patients
Type 2
diabetic
patients
n 121
Variables
Age (years) 78  6.7
Male/female sex 46/76
BMI (kg/m
2) 27.1  0.8
Systolic blood pressure
(mmHg)
145  6.1
Diastolic blood pressure
(mmHg)
85  3.8
Diabetes duration (years) 7.8  3.1
Risk factors
Hypertension 30 (25)
Hypercholesterolemia 13 (11)
Smokers 13 (11)
Previous CVD 38 (24)
Metabolic proﬁle
Fasting glycemia (mg/dl) 153  10.3
2-h PPG (mg/dl) 198  27.4
A1C (%) 7.9  0.3
MAGE (mg/dl glucose) 71  19
Fasting insulin (pmol/l) 170  55
Postmeal insulin (pmol/l) 398  109
Cognitive function
MMSE 26.1  1.3
TMT-A (s) 83  34
TMT-B (s) 187  85
DIFF B-A (s) 103  35
DSP-Backward 7.06  1.76
DSP-Forward 5.83  0.74
Verbal ﬂuency 25.7  4.49
Intimal-media thickness
(mm)
0.77  0.2
Data are means  SD, n,o rn (%).
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TMT-A [DIFF B-A]) provides a measure
ofcognitiveefﬁciency(15).TheWechsler
Adult Intelligence Scale–Revised Digit
Span is a measure of mental tracking as
wellasofbriefstorageandmentalmanip-
ulation (15). The Backward Digit Span
(DSP–Backward) requires the participant
listen to increasingly longer lists of digits
presented for immediate recall in the re-
verse order presented, whereas the For-
ward Digit Span (DSP–Forward) requires
immediate recall in the exact order pre-
sented. The Verbal Fluency Test requires
participants to generate as many words as
possiblein1minforagivenletter(F,A,S)
excluding nouns and variations of the
same word (16). Dementia was assessed
using a two-stage screening method. The
ﬁrst-stage screening was based on the
MMSE. According to Italian standards
(17), participants with an age- and edu-
cation-adjustedMMSEscoreof26were
considered to not have dementia and
those with a score of 26 were directed to
the second-stage screening that was per-
formed by a geriatrician and a psycholo-
gist with long-term experience in the
evaluation of older individuals with cog-
nitive problems. The diagnosis of “de-
mentia syndrome,” independent of
etiology was established using a standard
evaluationprotocolbasedonDSM-IVcri-
teria(18).Allparticipantswithdiagnosed
dementia were excluded from the
protocol.
Statistical analysis
All data are expressed as means  SD.
Plasma insulin and triglycerides were log
transformed for data analyses and back
transformed for data presentation. We
calculated the number of patients re-
quired for the study to reject the null hy-
pothesis 99% of the time (i.e., with a one-
tailed type II error rate of 0.01) when r
was 0.80 with a two-tailed type I error
at the 0.05 level of signiﬁcance. Because
this calculation led to a sample size of at
least110,thenumberofrequiredpatients
was set at 121. A cluster analysis, using
the squared sum of z scores, showed
whether an overall value obtained by
clustering attention and executive func-
tion test results was associated with
MAGE. To create such a cluster analysis,
we created a cognition composite score of
attention and executive functions, as sum
of the z scores of TMT-A, TMT-B, DIFF
B-A, DSP–Forward, DSP–Backward, and
Verbal Fluency. A z score indicates the
position of an individual value of a vari-
able in the total distribution of the vari-
ableinthepopulationandiscalculatedas
follows: (individual value – mean value)/
SD. The analysis transforms the individ-
ual test scores to z scores, summing these
and restandardizing this sum.
Multipleregressionmodelswereused
to explore the relationship between
MAGE and cognition (cognition compos-
itescoreandMMSEscore)independently
of several covariates. The effect of therapy
in patients categorized for number of an-
tidiabetes therapies was assessed by
ANOVA, and Ptrend was calculated. P 
0.05 was used of levels of signiﬁcance in
all tests performed.
RESULTS— The study group had
mean  SD age of 78  6.7 years (range
88–65 years), A1C of 7.9  0.3%, and
FPG of 153  10.3 mg/dl. A slightly
higher number of patients were women,
with modest overweight. According to
age most of them were affected by comor-
bidity (CVD that was not stroke-related;
13 reported hypercholesterolemia and 30
reported previous hypertension) (Table
1). No patients examined had carotid
plaque 70% (four patients had carotid
plaque at 20–25% without signiﬁcant al-
terationsinbloodﬂow)onacarotidultra-
sound examination or white matter
lesions or signiﬁcant signs of cortical or
subcortical atrophy with an MRI scan
(data not show). All patients were treated
with oral antidiabetes agents: glyburide
alone (10–15 mg/day in 19 patients) or
metformin alone (1,700 mg/day in 38 pa-
tients) or a combination of metformin
(1,700 mg/day) and glyburide (15 mg/
day) (in 51 patients) or a combination of
metformin (1,700 mg/day) and thiazo-
lidinediones (4 mg/day) (in 13 patients).
The MAGE over 24 h obtained from the
continuous glucose monitoring system in
the 121 patients was 71  19 mg/dl and
the 24-h glycemic value was 176  45
mg/dl.
Relationships among the cognition
composite score, MMSE score, and
markers of diabetic control
MAGE was signiﬁcantly correlated with
MMSE (r  0.83 P  0.001) and with the
cognition composite score (r  0.68, P 
0.001) (Fig. 1). This relationship per-
sisted after adjustment for the main an-
thropometric (BMI and waist-to-hip ratio
[WHR]), metabolic (FPG and 2-h PPG
and A1C), and/or vascular (mean arterial
blood pressure) covariables (data not
shown). No correlation between MAGE
and fasting insulin was observed (r 
0.02, P  0.1).
Figure 1—A: Relationship between MMSE and MAGE. B: Relationship between cognitive composite score and MAGE.
Rizzo and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 10, OCTOBER 2010 2171The independent effects of MAGE on
both the cognition composite and MMSE
scores were tested in three different mul-
tiple linear regression models (Table 2)
having,respectively,age,sex,BMI,WHR,
drug intake, physical activity, and MAGE
(model 1), model 1  systolic and dia-
stolic blood pressure (model 2), and
model 1 model 2  A1C, fasting and
postprandial glucose (model 3) as covari-
ates. In the more complex model 3 (Table
2),MAGEwasassociatedwithMMSEand
cognition composite score (indepen-
dently of age, sex, BMI, WHR, medica-
tion,physicalactivity,meanarterialblood
pressure, FPG, PPG, and A1C). This last
model explained 77 and 44% variability
of MMSE and cognition composite score,
respectively, whereas MAGE per se ex-
plained 24 and 26% variability of MMSE
and cognition, respectively. Among FPG,
PPG, and A1C, only PPG has been found
to be independently associated with cog-
nitive function (Table 2, model 3). All of
the analyses performed gave the same re-
sults, even after adjustment for education
level (data not shown).
Relationship between glucose
ﬂuctuation (MAGE) and therapy for
diabetes
To assess the impact of antidiabetes ther-
apy, all patients were categorized in three
groupsaccordingtonumberofantidiabe-
tes drugs used. No differences were ob-
served in the mean values of MAGE
according to antidiabetes treatment: gly-
buride, 70.2  29 mg/dl; metformin,
70.1  18 mg/dl; metformin plus gly-
buride, 71.7  16; or metformin plus
thiazolidinediones, 73.8  23. No differ-
ences in PPG, A1C, cognitive composite
score, and MMSE were found among the
study groups, thus showing a null impact
of therapy on MMSE score and cognition
composite score (data not shown).
CONCLUSIONS — Our study shows
thatimpairmentofcognitiveperformance
in older type 2 diabetic patients may be
associated with daily acute glucose ﬂuc-
tuations. In particular, MAGE excursions
were strongly correlated with cognitive
functioning, and this relationship was in-
dependent of the main markers of sus-
tained hyperglycemia (A1C, PPG, and
FPG). Even though a number of studies
have investigated and compared the roles
of the different glycemic indexes partici-
pating in diabetic cognitive disorders (2–
4),accurateassessmentoftheirrespective
contributionsisstillbeingdebated.Byus-
ing different methods, including epide-
miological (2), interventional (19), or
pathophysiological studies (5), several
authors have demonstrated that A1C is
Table 2—Linear multivariate analyses with MMSE and composite score as dependent variable
MMSE Composite score
B SEM  tP value B SEM  tP value
Model 1
Age 0.014 0.005 0.144 2.68 0.009 0.021 0.014 0.125 1.572 0.119
Sex 0.106 0.130 0.045 0.812 0.418 0.583 0.345 0.137 1.692 0.094
BMI 0.047 0.020 0.128 2.31 0.023 0.056 0.034 0.138 2.68 0.031
WHR 0.474 0.789 0.032 0.60 0.549 1.24 2.09 0.047 0.597 0.552
Drug intake 0.069 0.127 0.029 0.543 0.588 0.165 0.336 0.038 0.491 0.625
Physical activity 0.012 0.066 0.010 0.183 0.855 0.242 0.175 0.107 1.38 0.168
MAGE 0.044 0.003 0.746 13.04 0.000 0.059 0.009 0.556 6.57 0.000
Model 2
Age 0.014 0.005 0.142 2.77 0.007 0.022 0.014 0.129 1.60 0.112
Sex 0.161 0.124 0.068 1.30 0.195 0.57 0.348 0.135 1.64 0.104
BMI 0.056 0.020 0.152 2.84 0.005 0.047 0.025 0.111 2.36 0.004
WHR 1.00 0.764 0.068 1.31 0.193 1.34 2.114 0.051 0.635 0.527
Drug intake 0.053 0.121 0.022 0.44 0.660 0.159 0.340 0.037 0.468 0.641
Physical activity 0.006 0.064 0.005 0.09 0.921 0.238 0.177 0.105 1.344 0.182
MAGE 0.037 0.004 0.628 10.28 0.000 0.058 0.009 0.548 6.341 0.000
SBP 0.013 0.006 0.189 2.11 0.030 0.025 0.010 0.234 2.51 0.038
DBP 0.008 0.007 0.058 1.16 0.249 0.011 0.019 0.045 0.584 0.560
Model 3
Age 0.013 0.005 0.140 2.73 0.008 0.021 0.014 0.122 1.52 0.131
Sex 0.190 0.127 0.080 1.49 0.139 0.774 0.357 0.182 2.16 0.033
BMI 0.059 0.020 0.160 2.98 0.004 0.025 0.056 0.038 0.454 0.651
WHR 1.23 0.789 0.083 1.56 0.121 2.69 2.217 0.102 1.216 0.227
Drug intake 0.056 0.122 0.023 0.463 0.644 0.176 0.342 0.041 0.513 0.609
Physical activity 0.005 0.065 0.004 0.075 0.940 0.212 0.182 0.093 1.161 0.248
MAGE 0.037 0.004 0.635 10.31 0.000 0.050 0.010 0.472 4.88 0.000
SBP 0.005 0.003 0.071 1.424 0.158 0.004 0.010 0.031 0.394 0.695
DBP 0.008 0.007 0.058 1.168 0.246 0.017 0.019 0.067 0.858 0.393
A1C 0.037 0.080 0.027 0.458 0.648 0.084 0.225 0.034 0.372 0.711
PPG 0.006 0.002 0.167 2.581 0.011 0.028 0.009 0.205 2.37 0.025
Glucose 0.003 0.003 0.078 1.302 0.196 0.010 0.007 0.129 1.375 0.172
For MMSE: R
2  0.73 (model 1); R
2  0.73 (model 2); R
2  0.77 (model 3). For composite score: R
2  0.40 (model 1); R
2  0.41 (model 2); R
2  0.44 (model
3). SBP, systolic blood pressure; DBP, diastolic blood pressure.
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cline in cognitive performance in type 2
diabetes. For instance, it has been estab-
lished that chronic hyperglycemia in-
duces an overproduction of superoxide
which, after reacting with nitric oxide,
produces subsequent nitrosative stress
with generation of metabolic derivatives
such as peroxynitrite and nitrotyrosine
(20). The toxicity of these substances can
lead to neuronal damages and, further-
more, to a decline in cognitive perfor-
mance. In this context, daily glucose
ﬂuctuations, more generally, glucose
swings such as peaks and troughs, exhib-
ited a more speciﬁc triggering effect on
oxidative stress than chronic sustained
hyperglycemia (21). Thus, peaks, usually
corresponding to maximum values after
meals, and troughs, observed over inter-
prandial periods, could lead to continu-
ous production of oxidative stress,
impairing cognitive functioning. Oxida-
tivestresscausedbyfreeradicalsdamages
the endothelial cells in the blood vessels,
promotes lipid peroxidation, and plays a
central role in pathogenesis of cerebral
complications of type 2 diabetes. Various
studies have shown that increased oxida-
tive stress can lead to microvascular cere-
bral diseases, e.g., stroke, cerebral
hemorrhage, and brain infarction. The
reason for high risk of microvascular ce-
rebral diseases is that brain consumes
20%oftheoxygenconsumedbythebody
and has a low concentration of antioxi-
dants and high content of unsaturated
fatty acids and catecholamines that are
easily oxidized, making it more vulnera-
ble to oxidative damage than any other
organ in the body, and this may predis-
pose diabetic patients to development of
cognitive impairment (22). Because the
glycemic ﬂuctuations as estimated from
MAGE indexes reﬂect both upward and
downward glucose changes, whereas
A1C,PPG,andFPGvaluesareonlymark-
ers of upward variations, there is a reason
to hypothesize that MAGE indexes are
wider integrators of glycemic variations
than the A1C, PPG, and FPG values. Our
results, showing that MAGE values were
associated with cognitive functioning in-
dependently of the main markers of gly-
cemic control, seem to support such a
hypothesis. We therefore suggest that
acuteglycemicexcursionsshouldbeinte-
grated into glycemic disorders that are
larger than chronic hyperglycemia, i.e.,
into rapid glucose swings including de-
clines from relatively high glucose levels
duringpostprandialperiodstolowvalues
or even to asymptomatic hypoglycemia,
asobservedoverinterprandialperiods.As
a consequence, low glycemic levels in
type2diabetesmightalsoevokeadecline
in cognitive performance. Indeed, be-
cause the appropriate concentration of
glucose may have a pivotal role on meta-
bolic activity in the brain, the rapid glu-
cose swings from relatively high glucose
levels during postprandial periods to low
values or even to asymptomatic hypogly-
cemia and its associated neuroglycopenia
may contribute largely to a more rapid
decline of metabolic activity in the brain
(23) Thus, glucose variations over time,
ﬂuctuating from hyperglycemic peaks to
glucose nadirs, may affect cognitive func-
tion in older individuals, increasing oxi-
dative damage as well as altering the
appropriate brain supply of glucose.
These observations provide a possible ex-
planation for the independent role of
MAGE on cognitive function with respect
to PPG, FPG, and A1C.
In summary, the present study dem-
onstrates a signiﬁcant relationship be-
tween acute glucose swings and cognitive
performance impairment. A weakness in
thepresentstudyisitscross-sectional,ob-
servational nature, and it is therefore dif-
ﬁcult to draw causal relationships.
However, because the glycemic disorders
are risk factors for mild cognitive impair-
ment and both vascular dementia (1–5)
and Alzheimer disease, the present data
open the ﬁeld for conducting interven-
tional studies with the aim of treating gly-
cemicdisordersnotonlybyreducingA1C
and mean hyperglycemia (24) but also by
ﬂattening acute glucose ﬂuctuations.
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